GHRH Antagonists Boost Radiation's Power Against Lung Cancer Cells
Background
Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer-related deaths, with many patients developing resistance to conventional therapies like radiation. Growth Hormone-Releasing Hormone (GHRH) is a peptide hormone that, beyond its role in growth, has been implicated in promoting the proliferation and survival of various cancer cells, including those in NSCLC. GHRH receptors are often overexpressed in these tumors, suggesting a potential therapeutic target. Despite this, the specific impact of blocking GHRH signaling on the effectiveness of radiation therapy in NSCLC cells has not been fully elucidated. This study aimed to investigate whether GHRH antagonists could enhance the sensitivity of NSCLC cells to radiation.
Results
The study revealed that while MIA-602 alone had a modest inhibitory effect on cell proliferation (15% reduction at 100 nM), its combination with radiation significantly enhanced cell death. > The combination of MIA-602 and radiation led to a 43% greater reduction in NCI-H460 cell viability compared to radiation alone (p<0.001), demonstrating a strong synergistic effect. In A549 cells, the combined treatment increased apoptosis by 2.5-fold compared to radiation monotherapy (p<0.005), indicating enhanced programmed cell death. Furthermore, DNA damage markers, such as γH2AX foci, were elevated by 1.8-fold in cells treated with both MIA-602 and radiation, suggesting that the antagonist impairs DNA repair mechanisms and makes cells more vulnerable to radiation-induced damage. This synergistic effect was dose-dependent for MIA-602, with optimal results observed at 100 nM.
Why It Matters
This research highlights a promising new strategy to overcome radioresistance in NSCLC, a major challenge in oncology. By targeting the GHRH pathway, MIA-602 appears to sensitize cancer cells to radiation, potentially improving treatment outcomes for patients. The findings suggest that GHRH antagonists could be developed as novel adjuvant therapies to enhance the efficacy of radiotherapy in NSCLC. Future research should focus on validating these in vitro results in preclinical in vivo models (e.g., xenograft mouse models) to confirm safety and efficacy, paving the way for potential Phase I/II human clinical trials.